United States set
Menu Shopping cart $0 Search
Distributed product

QuickZyme Human MMP-2 Activity Assay Kit 96-Assays

  • Regulatory status:RUO
  • Type:ELISA
  • Other names:Matrix metalloproteinase-2, Gelatinase A, TBE-1, 72 kDa type IV collagenase, 72 kDa gelatinase, Gelatinase A, MMP-2, TBE-1, PEX, MMP2 CLG4A
  • Species:Human
Cat. No. Size Price

New QZBMMP2HV2 96 wells (1 kit) $1381,8
PubMed Product Details
Technical Data




The QuickZyme Human MMP-2 Activity Assay enables you to specifically measure in biological samples both active MMP-2, as well as (pro) MMP-2, which is activated on the plate by APMA. It can be used for the measurement of MMP-2 activity in various biological samples, such as conditioned culture media, tissue homogenates, serum, plasma and urine.

This 96-well plate format assay is based on the QuickZyme technology, using a modified pro-enzyme as a substrate, which upon activation is able to release color from a chromogenic peptide substrate. This multiplication step provides a unique assay sensitivity.


Serum, Urine, Plasma, Tissue homogenates, Cell culture conditioned medium

Sample Requirements

10 - 100 μl


On dry ice. Upon receipt, store the product at the temperature recommended below.


Unopened kit: Store at -20°C, except for the standard, this vial should be stored at -70°C. Do not use kit, or individual kit components past kit expiration date.

Opened kit / reconstituted reagents: Please refer to kit manual.

Calibration Range

0 - 16 ng/ml

Limit of Detection

0.04 ng/ml (2 hr incubation)

0.02 ng/ml (6 hr incubation)

4 pg/ml (o/n incubation)



  • Measures endogenous active MMP-2 ( naturally occurring ) or total active MMP-2 ( following activation with APMA ).

  • Samples: cell culture conditioned medium, serum, plasma, urine and tissue homogenates.

  • Quantitative.

  • Range: 0.02 – 16 ng/ml.

  • Sensitivity: 0.04 ng/ml for 2 h incubation with detection reagent; 0.02 ng/ml for 6 h incubation with detection reagent; 4 pg/ml for overnight incubation

  • Ease-of-use: Equivalent to ELISA.

Research topic

Bone and cartilage metabolism, Cardiovascular disease, Coronary artery disease, Extracellular matrix, Oncology


Matrix metalloproteinases (MMPs) are a family of zinc-dependent endopeptidases responsible for cleaving protein substrates, with the most commonly identified substrates being extracellular matrix (ECM) proteins. MMPs are involved in normal physiological processes, such embryogenesis, organogenesis during development, reproduction tissue resorption, wound healing and tissue remodeling. They also play a role in a number of pathological processes such as inflammation, arthritis, cardiovascular diseases, fibrosis and cancer.

In addition to modulating the components of the extracellular connective tissue, MMPs also regulate cell proliferation, differentiation, migration, apoptosis, and vessel regeneration indirectly by cleaving and activating vital molecules that control cell function, or directly by binding to cell surface molecules that trigger activation of intracellular pathways.

Regulation of MMPs is carried out at various levels. Expression of latent MMPs is regulated at the level of transcription, whereas the proteolytic activity is controlled by specific activation of proMMPs, and by MMP-specific inhibitors, the tissue inhibitors of metalloproteinases (TIMPs), or general circulatory inhibitors, such as α2macroglobulin. The MMPs can be grouped according to their domain structure into collagenases, gelatinases, stromelysins, membrane type MMPs and matrilysins.

MMP-2 (also known as 72 kDa type IV collagenase, Gelatinase A; EC degrades collagen IV, V, VII and X, as well as elastic, fibronectin, and denatured collagen type I. Human MMP-2 has a Mw of 72 kDa (proform) and 62 kDa (active form). The activity is dependent on Zn2+ and Ca2+. MMP-2 is secreted as proMMP-2, and can be activated in vitro by organo mercurial compounds such as p-aminophenyl mercuric acetate (APMA). MMP-2 is produced by a variety of cell types including fibroblasts, chondrocytes, endothelial and epithelial cells.

MMP-2 is expressed by various liver cells, most abundantly by HSCs and KCs, and is one of the widely studied enzymes in liver fibrosis. Several studies evidently correlated the expression of MMP-2 to the progression of fibrosis, regardless of the etiology (with no detectable expression in normal livers), implicating its profibrogenic properties. Increased MMP-2 expression has been associated with chronic hepatitis, liver fibrosis, alcoholic liver cirrhosis, ischemia and reperfusion injury (IRI), and biliary atresia (BA) (progressive fibroinflammatory cholangiopathy of infancy and a leading indication for pediatric liver transplantation).

The expression of MMP-2 has been strongly associated with the progression of malignancy of several types of carcinoma. In primary skin melanoma, lung carcinoma, ovarian carcinoma and brain neoplasms, the expression of the immunoreactive protein for MMP-2 was associated with a poor prognosis. In several studies, MMP-2 has been shown to be expressed in breast carcinoma and it has been localised in breast carcinoma cells using immunohistochemical methods. MMP-2 is commonly cited, along with MMP-9, for involvement in the epithelial-mesenchymal transition (EMT) process many malignant tumors, including hepatocellular carcinoma (HCC).

Summary References (37)

References to MMP-2

  • Aschner Y, Zemans RL, Yamashita CM, Downey GP. Matrix metalloproteinases and protein tyrosine kinases: potential novel targets in acute lung injury and ARDS. Chest. 2014 Oct;146(4):1081-1091. doi: 10.1378/chest.14-0397. PMID: 25287998; PMCID: PMC4188143. See more on PubMed
  • Clark IM, Swingler TE, Sampieri CL, Edwards DR. The regulation of matrix metalloproteinases and their inhibitors. Int J Biochem Cell Biol. 2008;40(6-7):1362-78. doi: 10.1016/j.biocel.2007.12.006. Epub 2007 Dec 24. PMID: 18258475. See more on PubMed
  • Cursio R, Mari B, Louis K, Rostagno P, Saint-Paul MC, Giudicelli J, Bottero V, Anglard P, Yiotakis A, Dive V, Gugenheim J, Auberger P. Rat liver injury after normothermic ischemia is prevented by a phosphinic matrix metalloproteinase inhibitor. FASEB J. 2002 Jan;16(1):93-5. doi: 10.1096/fj.01-0279fje. Epub 2001 Nov 14. PMID: 11709491. See more on PubMed
  • Daidone MG, Silvestrini R, D'Errico A, Di Fronzo G, Benini E, Mancini AM, Garbisa S, Liotta LA, Grigioni WF. Laminin receptors, collagenase IV and prognosis in node-negative breast cancers. Int J Cancer. 1991 Jun 19;48(4):529-32. doi: 10.1002/ijc.2910480409. PMID: 1646175. See more on PubMed
  • Davidson B, Goldberg I, Gotlieb WH, Kopolovic J, Ben-Baruch G, Nesland JM, Berner A, Bryne M, Reich R. High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma. Clin Exp Metastasis. 1999;17(10):799-808. doi: 10.1023/a:1006723011835. PMID: 11089877. See more on PubMed
  • Davies B, Miles DW, Happerfield LC, Naylor MS, Bobrow LG, Rubens RD, Balkwill FR. Activity of type IV collagenases in benign and malignant breast disease. Br J Cancer. 1993 May;67(5):1126-31. doi: 10.1038/bjc.1993.207. PMID: 8494711; PMCID: PMC1968428. See more on PubMed
  • DeCoux A, Lindsey ML, Villarreal F, Garcia RA, Schulz R. Myocardial matrix metalloproteinase-2: inside out and upside down. J Mol Cell Cardiol. 2014 Dec;77:64-72. doi: 10.1016/j.yjmcc.2014.09.016. Epub 2014 Sep 28. PMID: 25261607; PMCID: PMC4312173. See more on PubMed
  • D'Errico A, Garbisa S, Liotta LA, Castronovo V, Stetler-Stevenson WG, Grigioni WF. Augmentation of type IV collagenase, laminin receptor, and Ki67 proliferation antigen associated with human colon, gastric, and breast carcinoma progression. Mod Pathol. 1991 Mar;4(2):239-46. PMID: 1646457. See more on PubMed
  • Ellenrieder V, Alber B, Lacher U, Hendler SF, Menke A, Boeck W, Wagner M, Wilda M, Friess H, Büchler M, Adler G, Gress TM. Role of MT-MMPs and MMP-2 in pancreatic cancer progression. Int J Cancer. 2000 Jan 1;85(1):14-20. doi: 10.1002/(sici)1097-0215(20000101)85:1<14::aid-ijc3>3.0.co;2-o. PMID: 10585576. See more on PubMed
  • Garbett EA, Reed MW, Brown NJ. Proteolysis in human breast and colorectal cancer. Br J Cancer. 1999 Sep;81(2):287-93. doi: 10.1038/sj.bjc.6690689. PMID: 10496354; PMCID: PMC2362855. See more on PubMed
  • Garbett EA, Reed MW, Stephenson TJ, Brown NJ. Proteolysis in human breast cancer. Mol Pathol. 2000 Apr;53(2):99-106. doi: 10.1136/mp.53.2.99. PMID: 10889910; PMCID: PMC1186913. See more on PubMed
  • Geervliet E, Bansal R. Matrix Metalloproteinases as Potential Biomarkers and Therapeutic Targets in Liver Diseases. Cells. 2020 May 13;9(5):1212. doi: 10.3390/cells9051212. PMID: 32414178; PMCID: PMC7290342. See more on PubMed
  • Giannelli G, Bergamini C, Marinosci F, Fransvea E, Quaranta M, Lupo L, Schiraldi O, Antonaci S. Clinical role of MMP-2/TIMP-2 imbalance in hepatocellular carcinoma. Int J Cancer. 2002 Feb 1;97(4):425-31. doi: 10.1002/ijc.1635. PMID: 11802202. See more on PubMed
  • Höyhtyä M, Fridman R, Komarek D, Porter-Jordan K, Stetler-Stevenson WG, Liotta LA, Liang CM. Immunohistochemical localization of matrix metalloproteinase 2 and its specific inhibitor TIMP-2 in neoplastic tissues with monoclonal antibodies. Int J Cancer. 1994 Feb 15;56(4):500-5. doi: 10.1002/ijc.2910560408. PMID: 8112886. See more on PubMed
  • Huang CC, Chuang JH, Chou MH, Wu CL, Chen CM, Wang CC, Chen YS, Chen CL, Tai MH. Matrilysin (MMP-7) is a major matrix metalloproteinase upregulated in biliary atresia-associated liver fibrosis. Mod Pathol. 2005 Jul;18(7):941-50. doi: 10.1038/modpathol.3800374. PMID: 15696117. See more on PubMed
  • Chen Q, Jin M, Yang F, Zhu J, Xiao Q, Zhang L. Matrix metalloproteinases: inflammatory regulators of cell behaviors in vascular formation and remodeling. Mediators Inflamm. 2013;2013:928315. doi: 10.1155/2013/928315. Epub 2013 Jun 12. PMID: 23840100; PMCID: PMC3694547. See more on PubMed
  • Iwata H, Kobayashi S, Iwase H, Masaoka A, Fujimoto N, Okada Y. Production of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human breast carcinomas. Jpn J Cancer Res. 1996 Jun;87(6):602-11. doi: 10.1111/j.1349-7006.1996.tb00266.x. PMID: 8766524; PMCID: PMC5921148. See more on PubMed
  • Jäälinojä J, Herva R, Korpela M, Höyhtyä M, Turpeenniemi-Hujanen T. Matrix metalloproteinase 2 (MMP-2) immunoreactive protein is associated with poor grade and survival in brain neoplasms. J Neurooncol. 2000;46(1):81-90. doi: 10.1023/a:1006421112839. PMID: 10896208. See more on PubMed
  • Jacob-Ferreira AL, Schulz R. Activation of intracellular matrix metalloproteinase-2 by reactive oxygen-nitrogen species: Consequences and therapeutic strategies in the heart. Arch Biochem Biophys. 2013 Dec;540(1-2):82-93. doi: 10.1016/j.abb.2013.09.019. Epub 2013 Oct 5. PMID: 24103691. See more on PubMed
  • Jones JL, Glynn P, Walker RA. Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas. J Pathol. 1999 Oct;189(2):161-8. doi: 10.1002/(SICI)1096-9896(199910)189:2<161::AID- PATH406>3.0.CO;2-2. PMID: 10547569. See more on PubMed
  • Kodate M, Kasai T, Hashimoto H, Yasumoto K, Iwata Y, Manabe H. Expression of matrix metalloproteinase (gelatinase) in T1 adenocarcinoma of the lung. Pathol Int. 1997 Jul;47(7):461-9. doi: 10.1111/j.1440-1827.1997.tb04525.x. PMID: 9234385. See more on PubMed
  • Levy AT, Cioce V, Sobel ME, Garbisa S, Grigioni WF, Liotta LA, Stetler- Stevenson WG. Increased expression of the Mr 72,000 type IV collagenase in human colonic adenocarcinoma. Cancer Res. 1991 Jan 1;51(1):439-44. PMID: 1846313. See more on PubMed
  • Lichtinghagen R, Bahr MJ, Wehmeier M, Michels D, Haberkorn CI, Arndt B, Flemming P, Manns MP, Boeker KH. Expression and coordinated regulation of matrix metalloproteinases in chronic hepatitis C and hepatitis C virus-induced liver cirrhosis. Clin Sci (Lond). 2003 Sep;105(3):373-82. doi: 10.1042/CS20030098. PMID: 12760742. See more on PubMed
  • Liotta LA, Stetler-Stevenson WG. Metalloproteinases and cancer invasion. Semin Cancer Biol. 1990 Apr;1(2):99-106. PMID: 2103492. See more on PubMed
  • Liu HL, Li XH, Wang DY, Yang SP. Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 expression in fibrotic rat liver. World J Gastroenterol. 2000 Dec;6(6):881-884. doi: 10.3748/wjg.v6.i6.881. PMID: 11819713; PMCID: PMC4728279. See more on PubMed
  • Löffek S, Schilling O, Franzke CW. Series "matrix metalloproteinases in lung health and disease": Biological role of matrix metalloproteinases: a critical balance. Eur Respir J. 2011 Jul;38(1):191-208. doi: 10.1183/09031936.00146510. Epub 2010 Dec 22. PMID: 21177845. See more on PubMed
  • Monteagudo C, Merino MJ, San-Juan J, Liotta LA, Stetler-Stevenson WG. Immunohistochemical distribution of type IV collagenase in normal, benign, and malignant breast tissue. Am J Pathol. 1990 Mar;136(3):585-92. PMID: 2156430; PMCID: PMC1877499. See more on PubMed
  • Perlikos F, Harrington KJ, Syrigos KN. Key molecular mechanisms in lung cancer invasion and metastasis: a comprehensive review. Crit Rev Oncol Hematol. 2013 Jul;87(1):1-11. doi: 10.1016/j.critrevonc.2012.12.007. Epub 2013 Jan 16. PMID: 23332547. See more on PubMed
  • Prystupa A, Boguszewska-Czubara A, Bojarska-Junak A, Toruń-Jurkowska A, Roliński J, Załuska W. Activity of MMP-2, MMP-8 and MMP-9 in serum as a marker of progression of alcoholic liver disease in people from Lublin Region, eastern Poland. Ann Agric Environ Med. 2015;22(2):325-8. doi: 10.5604/12321966.1152088. PMID: 26094532. See more on PubMed
  • Sakata K, Shigemasa K, Nagai N, Ohama K. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary. Int J Oncol. 2000 Oct;17(4):673-81. PMID: 10995877. See more on PubMed
  • Scheau C, Badarau IA, Costache R, Caruntu C, Mihai GL, Didilescu AC, Constantin C, Neagu M. The Role of Matrix Metalloproteinases in the Epithelial- Mesenchymal Transition of Hepatocellular Carcinoma. Anal Cell Pathol (Amst). 2019 Nov 26;2019:9423907. doi: 10.1155/2019/9423907. PMID: 31886121; PMCID: PMC6899323. See more on PubMed
  • Takahara T, Furui K, Funaki J, Nakayama Y, Itoh H, Miyabayashi C, Sato H, Seiki M, Ooshima A, Watanabe A. Increased expression of matrix metalloproteinase-II in experimental liver fibrosis in rats. Hepatology. 1995 Mar;21(3):787-95. PMID: 7875677. See more on PubMed
  • Takahara T, Furui K, Yata Y, Jin B, Zhang LP, Nambu S, Sato H, Seiki M, Watanabe A. Dual expression of matrix metalloproteinase-2 and membrane-type 1-matrix metalloproteinase in fibrotic human livers. Hepatology. 1997 Dec;26(6):1521-9. doi: 10.1002/hep.510260620. PMID: 9397993. See more on PubMed
  • Takahashi Y, Kobayashi T, D'Alessandro-Gabazza CN, Toda M, Fujiwara K, Okano T, Fujimoto H, Asayama K, Takeshita A, Yasuma T, Nishihama K, Inoue R, Qin L, Takei Y, Taguchi O, Gabazza EC. Protective Role of Matrix Metalloproteinase-2 in Allergic Bronchial Asthma. Front Immunol. 2019 Aug 2;10:1795. doi: 10.3389/fimmu.2019.01795. PMID: 31428095; PMCID: PMC6687911. See more on PubMed
  • Talvensaari-Mattila A, Pääkkö P, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. Br J Cancer. 2003 Oct 6;89(7):1270-5. doi: 10.1038/sj.bjc.6601238. PMID: 14520459; PMCID: PMC2394290. See more on PubMed
  • Tryggvason K, Höyhtyä M, Pyke C. Type IV collagenases in invasive tumors. Breast Cancer Res Treat. 1993;24(3):209-18. doi: 10.1007/BF01833261. PMID: 8435476. See more on PubMed
  • Väisänen A, Kallioinen M, Taskinen PJ, Turpeenniemi-Hujanen T. Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma. J Pathol. 1998 Sep;186(1):51-8. doi: 10.1002/(SICI)1096-9896(199809)186:1<51::AID-PATH131>3.0.CO;2-P. PMID: 9875140. See more on PubMed
Related Products Docs